The biotech market is very interesting, especially when you compare and contrast the market cap of companies and their respective pipelines. I understand CYDY has been diluting for some time, but leronlimab is close to approval and CYDY will finally have revenue. Factor in the prostate test and pending cancer trials, CYDY should be much higher. I sometimes ask myself if I’m missing something, but can’t come up with anything.

Are our expectations for market share too high? Will the revenue not be enough to actually make the company more valuable then it is? I can’t figure it out, but I’m hopeful that CYDY can only go up from here.